Moleculin Biotech
MBRX
MBRX
24 hedge funds and large institutions have $3.17M invested in Moleculin Biotech in 2022 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 4 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
Holders
24
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$38.8K | |
| 2 | +$15K | |
| 3 | +$3.07K | |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$858 |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$636 |
Top Sellers
| 1 | -$21K | |
| 2 | -$12K | |
| 3 | -$6.41K | |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$4.94K |
| 5 |
Osaic Holdings
Scottsdale,
Arizona
|
-$4.33K |